8LY.F ONCOZENGE AB
- Market cap
- EUR 7.11M
- P/E
- -
- P/B
- 8.00x
- ROE
- -261.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 8LY.F undervalued?
Graham numberThe Graham number of ONCOZENGE AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ONCOZENGE AB fundamental analysis
No fundamental analysis for ONCOZENGE AB yet.
ONCOZENGE AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ONCOZENGE AB
OncoZenge AB (publ), is a clinical-stage pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. The company offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was founded in 2020 and is headquartered in Bromma, Sweden.
Full company profileONCOZENGE AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ONCOZENGE AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 2.66M | 11.7M |
| Gross Profit | 0.00 | 0.00 | - | - | - | - |
| Operating Income | -4.89M | -20.4M | -15.9M | -8.69M | -15.8M | -24.5M |
| EBITDA | - | -20.4M | -15.9M | -8.68M | -15.8M | -24.5M |
| Net Income | -3.89M | -46.6M | -15.9M | -8.69M | -15.9M | -25.6M |
| EPS | -0.33 | -3.98 | -1.36 | -0.74 | -1.26 | -1.82 |
| Balance Sheet | ||||||
| Total Assets | 85.2M | 36.9M | 20.3M | 11.4M | 24.4M | 26.8M |
| Total Liabilities | 4.90M | 2.92M | 1.70M | 1.48M | 15.9M | 17.0M |
| Shareholders' Equity | 80.3M | 34.0M | 18.6M | 9.95M | 8.48M | 9.80M |
| Cash & Short-term Investments | 51.2M | 29.1M | 12.6M | 3.86M | 3.71M | 749K |
| Cash Flow | ||||||
| Operating Cash Flow | -4.77M | -22.1M | -17.1M | -8.76M | -13.1M | -26.1M |
| Capital Expenditure | 5.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -10.1M | -22.1M | -17.1M | -8.76M | -13.1M | -26.1M |
| Ratios | ||||||
| ROE | -4.8% | -137.3% | -85.3% | -87.3% | -188.0% | -261.1% |
| ROA | -4.6% | -126.4% | -78.2% | -76.0% | -65.3% | -95.4% |
| Net Profit Margin | - | - | - | - | -598.3% | -219.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ONCOZENGE AB dividends
ONCOZENGE AB has not paid dividends in the last 5 fiscal years.
Who owns ONCOZENGE AB
- Insiders 28.21%
- Institutions 7.91%
- Public & others 63.88%
- Shares outstanding 25.0M
- Free float 10.1M
ONCOZENGE AB company profile
- Company name
- ONCOZENGE AB
- Ticker
- 8LY.F
- ISIN
- SE0015504097
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- Gustavslundsvägen 34, 5 tr, Bromma, Sweden, 167 51
- Phone
- 46 8 31 14 20
- Website
- oncozenge.com
About ONCOZENGE AB
OncoZenge AB (publ), is a clinical-stage pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. The company offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was founded in 2020 and is headquartered in Bromma, Sweden.
ONCOZENGE AB management
6- Mr. Stian KildalChief Executive Officer · born 1976
- Mr. Michael Owens B.A., B.S., B.S.B.AChief Financial Officer · born 1956
- Ida SparrfeldtChief Auditor · born 1986
- Ms. Tuulikki LindmarkHead of CMC in Phase 3 Sponsor Team
- Dr. Marie-Louise Helena Fjallskog M.D., Ph.D.Chief Medical Officer · born 1964
- Ms. Linda NordHead of Regulatory Affairs